Bioniche Life Sciences puts Irish unit up for sale

Guest Contributor
October 3, 2005

Bioniche Life Sciences Inc, Belleville ON, is placing its majority stake in Bioniche Pharma Group Ltd, Galway Ireland, to generate revenue to support the parent’s R&D projects. The announcement was made as the firm announced its financial results for fiscal 2005, ending June 30. If a buyer is secured, Bioniche will use the proceeds to fund Phase III trials for its compound for bladder cancer and license its E.coli vaccine for cattle. Bioniche’s 2005 revenue was $30.3 million, a 2% decrease from 2004. The Irish manufacturing operation contributed $18.6 million, down from $24.6 million in 2004. R&D expenses increased 11.6% to $12.8 million, less $1 million in government incentives. Bioniche recently repaid nearly $465,000 to Technology Partnerships Canada (TPC) following revelations that it had paid lobbyist and former Liberal Cabinet minister David Dingwall $350,000 to secure support for its R&D projects. The resolution means Bioniche will receive the remaining $2 million of its $17.2 million in TPC assistance….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.